CHICAGO — Extended-release quetiapine monotherapy at 50 mg or 150 mg once daily is rapidly effective and well tolerated with minimal metabolic side effects in patients with generalized anxiety disorder, as demonstrated in a large phase III clinical trial.
PREVIEW